These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17062843)

  • 1. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E687-92. PubMed ID: 17062843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calculating energy requirements for men with HIV/AIDS in the era of highly active antiretroviral therapy.
    Batterham MJ; Morgan-Jones J; Greenop P; Garsia R; Gold J; Caterson I
    Eur J Clin Nutr; 2003 Feb; 57(2):209-17. PubMed ID: 12571651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
    Yki-Järvinen H; Sutinen J; Silveira A; Korsheninnikova E; Fisher RM; Kannisto K; Ehrenborg E; Eriksson P; Hamsten A
    Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):688-94. PubMed ID: 12615670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome.
    Kosmiski LA; Kuritzkes DR; Sharp TA; Hamilton JT; Lichtenstein KA; Mosca CL; Grunwald GK; Eckel RH; Hill JO
    Metabolism; 2003 May; 52(5):620-5. PubMed ID: 12759894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
    Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Energy expenditure, substrate oxidation, and body composition in subjects with chronic alcoholism: new findings from metabolic assessment.
    Addolorato G; Capristo E; Greco AV; Stefanini GF; Gasbarrini G
    Alcohol Clin Exp Res; 1997 Sep; 21(6):962-7. PubMed ID: 9309302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
    Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
    Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
    Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
    Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy.
    Johnson JA; Albu JB; Engelson ES; Fried SK; Inada Y; Ionescu G; Kotler DP
    Am J Physiol Endocrinol Metab; 2004 Feb; 286(2):E261-71. PubMed ID: 14532165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure.
    van der Valk M; Reiss P; van Leth FC; Ackermans MT; Endert E; Romijn JA; Heijligenberg R; Sauerwein H
    J Clin Endocrinol Metab; 2002 Nov; 87(11):5066-71. PubMed ID: 12414873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy.
    Luzi L; Perseghin G; Tambussi G; Meneghini E; Scifo P; Pagliato E; Del Maschio A; Testolin G; Lazzarin A
    Am J Physiol Endocrinol Metab; 2003 Feb; 284(2):E274-80. PubMed ID: 12388139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term energy restriction reduces resting energy expenditure in patients with HIV lipodystrophy and hypermetabolism.
    Kosmiski LA; Bessesen DH; Stotz SA; Koeppe JR; Horton TJ
    Metabolism; 2007 Feb; 56(2):289-95. PubMed ID: 17224345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy.
    Cossarizza A; Riva A; Pinti M; Ammannato S; Fedeli P; Mussini C; Esposito R; Galli M
    Antivir Ther; 2003 Aug; 8(4):315-21. PubMed ID: 14518701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial.
    Simons JP; Schols AM; Hoefnagels JM; Westerterp KR; ten Velde GP; Wouters EF
    Cancer; 1998 Feb; 82(3):553-60. PubMed ID: 9452274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
    Andersen O; Haugaard SB; Flyvbjerg A; Andersen UB; Ørskov H; Madsbad S; Nielsen JO; Iversen J
    Eur J Clin Invest; 2004 Aug; 34(8):561-8. PubMed ID: 15305891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
    Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on HIV/HAART associated morphologic and metabolic abnormalities.
    Falutz J
    Forum Nutr; 2003; 56():158-62. PubMed ID: 15806844
    [No Abstract]   [Full Text] [Related]  

  • 20. [The influence of long-term nucleotide reverse transcriptase inhibitors on lipids metabolism in HIV/AIDS patients].
    Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
    Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):859-62. PubMed ID: 23291022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.